Company overview
BioSpring is a contract manufacturing organization (CMO) based in Frankfurt, Germany, specializing in therapeutic oligonucleotide and mRNA synthesis since 1997. The company provides GMP-compliant manufacturing, analytical services, and quality control for antisense, siRNA, conjugates, and long single-stranded RNA applications across preclinical, clinical, and commercial stages. BioSpring operates cGMP cleanrooms and offers both small-scale and large-scale production with advanced LC-MS workflows and compliance-ready processes.
Oligonucleotide & mRNA Manufacturing CMO is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include oligonucleotide manufacturing, mrna synthesis, gmp contract manufacturing, therapeutic oligonucleotides, sirna production.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Oligonucleotide & mRNA Manufacturing CMO include Synthesis — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.biospring.net
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- oligonucleotide manufacturing, mrna synthesis, gmp contract manufacturing, therapeutic oligonucleotides, sirna production
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What types of oligonucleotides does BioSpring manufacture?
- BioSpring manufactures therapeutic oligonucleotides including antisense, siRNA, conjugates, and long single-stranded RNA for preclinical, diagnostic, and commercial applications. The company recently expanded capabilities to include next-generation oligonucleotides using Luxna's XNA technology, which offers improved binding affinity, increased stability, and reduced toxicity.
- What regulatory compliance and quality standards does BioSpring maintain?
- BioSpring operates cGMP-certified facilities with three independent cGMP cleanrooms for oligonucleotide manufacturing. The company provides GMP-compliant material and implements compliance-ready LC-MS workflows for analytical testing, ensuring regulatory compliance from early development through commercial production.
- What is BioSpring's manufacturing capacity and scale?
- BioSpring supports both small-scale and large-scale manufacturing with robust upstream and downstream processing capabilities. The company has undergone rapid expansion in recent years to meet growing demand for oligonucleotide synthesis and offers tailored solutions for projects at any development stage.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
